Capital International Investors Sage Therapeutics, Inc. Transaction History

Capital International Investors

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$70.65 - $96.76 $4.88 Million - $6.68 Million	-69,010 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$41.13 - $62.45 $15.1 Million - $22.9 Million	-366,301 Reduced 84.15%	69,010 $4.22 Million
Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $84.1 Million - $140 Million	-3,241,036 Reduced 88.16%	435,311 $18.1 Million
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $3.6 Million - $10.6 Million	-137,729 Reduced 3.61%	3,676,347 $106 Million
Q4 2019 Feb 18, 2020	BUY	$60.18 - $154.77 $9.45 Million - $24.3 Million	157,060 Added 4.29%	3,814,076 $275 Million
Q3 2019 Nov 14, 2019	BUY	$140.29 - $189.96 $72.5 Million - $98.2 Million	516,724 Added 16.45%	3,657,016 $513 Million
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $496 Million - $575 Million	3,140,292 New	3,140,292 $575 Million

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Capital International Investors, based on Form 13F filings with the SEC.

Stay updated on Capital International Investors with notifications on news.